Year in Review: Top 20 reimbursed medicines by gross spend

Rank	Medicine	Therapeutic Group	2019/20
			$
1	Glecaprevir and pibrentasvir (Maviret)	Antivirals	$129,320,000
2	Adalimumab	Immunosuppressants	$98,720,000
3	Dabigatran	Antithrombotic Agents	$45,480,000
4	Pembrolizumab	Immunosuppressants	$42,160,000
5	Trastuzumab	Immunosuppressants	$35,740,000
6	Insulin glargine	Diabetes	$34,150,000
7	Pneumococcal vaccine	Vaccinations	$33,300,000
8	Etanercept	Immunosuppressants	$30,910,000
9	Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	Vaccinations	$26,300,000
10	Abiraterone acetate	Oncology	$25,450,000
11	Lenalidomide	Oncology	$25,370,000
12	Budesonide with eformoterol	Respiratory	$24,970,000
13	Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	Vaccinations	$23,120,000
14	Fluticasone with salmeterol	Respiratory	$23,040,000
15	Rurioctocog alfa pegol [Recombinant factor VIII]	Blood & Blood Forming Organs	$21,860,000
16	Rituximab	Immunosuppressants	$18,540,000
17	Rivaroxaban	Antithrombotic Agents	$16,790,000
18	Dolutegravir	Anti-infectives	$16,470,000
19	Paliperidone	Anti-psychotics	$15,400,000
20	Aflibercept	Immunosuppressants	$15,170,000
		Totals	$702,260,000

The data above excludes hospital purchases.

Gross spend is shown in millions NZD, is exclusive of GST, and prior to the application of rebates and discounts.

This data can change as prior year adjustments are made.

(1) This figure is based on the listed price and estimated units at dispensing.